Healthcare Review: Ariad Pharmaceuticals, Rosetta Genomics, Gilead Sciences, Acura, Infinity Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Monday, 09 December 2013 11:46
Stocks inched higher as investors digested the previous session's big gains, awaited speeches from a number of Federal Reserve Bank presidents and looked ahead to the prospect of a budget deal later this week. The Dow Jones Industrial Average rose 17 points, or 0.1%, to 16037 in recent trade. On Friday, the Dow surged 199 points, or 1.3%, to post the biggest one-day gain since Oct. 16 and snap a five-session losing streak. There were no major economic data scheduled for release Monday. But investors will keep tabs on speeches from Fed bank presidents Jeffrey Lacker, Richard Fisher and James Bullard, later in the session, as a potential source of guidance on the Fed's policy intentions.

Jefferies hikes its price target on Ariad Pharmaceuticals ($ARIA) to $4 from $2.50. Hold rating reiterated."Although timing of FDA's decision to return Iclusig to market remains uncertain, physicians expect a new label to be broader than just T315iM pts," analyst Eun Yang says.

Rosetta Genomics ($ROSG) soars 20% as the company says the New York State Department of Health has granted conditional approval for ROSG's kidney cancer test.

"With this approval, [we] can offer the Rosetta Kidney Cancer Test in all 50 U.S. states," the company says.

Fresh off FDA approval for the game-changing HCV treatment sofosbuvir, Gilead Sciences ($GILD) reports (at ASH) interim results from a Phase 2 study of the Syk inhibitor GS-9973 in relapsed or refractory hematologic malignancies. Results: 97% of CLL patients receiving at least eight weeks of therapy saw lymph node reduction, 20% saw a 50% or greater reduction in their tumors, and, regarding safety, in a population of 78 CLL and NHL patients receiving at least four weeks of therapy, 64% continued treatment. (PR)Also at ASH, GILD reported results from a Phase 2 study of the PI3K inhibitor idelalisib in refractory iNHL. OR rate: 57%, medium duration 12.5 months; CRs, 6%; 63% had a partial response. Median PFS: 11 months; median OS, 20.3 months.

Acura's ($ACUR) shares surge 5% after the FDA agrees to review the results of the failed Phase II trial of a painkiller that was made with the company's Aversion technology, which is designed to deter drug abuse. The results of the study showed that Acura's tablet did not significantly lower likability among abusers. The FDA has now agreed to provide a definitive response regarding the suitability of the study that will be used to consider authorization of Acura's product. The agency has requested extra data, although the company doesn't believe it will need to carry out additional studies.

Infinity Pharmaceuticals ($INFI) reports preclinical data that demonstrates the activity of IPI-145 (PI3K inhibitor) in models of DLBCL and T-ALL.INFI also says Phase 1 data in a NHL shows the treatment "led to a reduction in adenopathy" in three of eight DLBCL patients and two of three with Richter transformation.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter